2f:I[703058,["/_next/static/immutable/chunks/3bhq_5eh1d760.js","/_next/static/immutable/chunks/1855-ogyi8eh4.js","/_next/static/immutable/chunks/2pfsjpn6k6zlg.js","/_next/static/immutable/chunks/26c7v3_3uwnwu.js","/_next/static/immutable/chunks/25a3ozcrvi1ff.js","/_next/static/immutable/chunks/2r4wx50nvjh_4.js","/_next/static/immutable/chunks/23fsw06hsi5b1.js","/_next/static/immutable/chunks/06_yt270h41rg.js","/_next/static/immutable/chunks/3ezsiz-7shkna.js","/_next/static/immutable/chunks/20x2y96ldu5wx.js","/_next/static/immutable/chunks/2lxntcm3pd1_h.js","/_next/static/immutable/chunks/00dgco8irq3jw.js","/_next/static/immutable/chunks/00nwe-kq0rboc.js","/_next/static/immutable/chunks/2051ffx3xzio9.js"],"PaperListPageClient"] 30:T67b,Since 1991, the CDC has recommended screening for hepatitis B virus (HBV) infection in pregnancy and universal hepatitis B vaccination of all medically stable infants at birth, serving as a core strategy to prevent perinatal and postnatal infection and eliminate HBV transmission nationwide. On December 5, 2025, the Advisory Committee on Immunization Practices (ACIP) voted (1) among women who screen negative in pregnancy, parents decide, in consultation with providers, when or if to vaccinate their child for hepatitis B, and if not at birth, then aged no earlier than 2 months, and (2) consider collection of infant immune titers to guide decision-making for completing the vaccine series. We conducted a comprehensive review of the evidence on the safety, immunogenicity, efficacy, and effectiveness of the birth dose and a delayed first dose, and of the potential role of serology for clinical decision-making. We analyzed studies of the epidemiology of HBV infection, clinical trials, systematic reviews, vaccine safety from surveillance and clinical studies, and the potential impact of revised guidelines on individual and public health. We synthesized the history of ACIP recommendations and resulting trends in HBV incidence. The review found strong evidence for the safety and effectiveness of the birth dose, and no improvement in safety or effectiveness with a delayed first dose. We found no evidence to support the use of postvaccination serology. Infant vaccination has resulted in a 99% reduction in pediatric HBV infections; we found no evidence to support a change in vaccine recommendations but identified potential health consequences.31:T748, Since 1991, the CDC has recommended screening for hepatitis B virus (HBV) infection in pregnancy and universal hepatitis B vaccination of all medically stable infants at birth, serving as a core strategy to prevent perinatal and postnatal infection and eliminate HBV transmission nationwide. On December 5, 2025, the Advisory Committee on Immunization Practices (ACIP) voted (1) among women who screen negative in pregnancy, parents decide, in consultation with providers, when or if to vaccinate their child for hepatitis B, and if not at birth, then aged no earlier than 2 months, and (2) consider collection of infant immune titers to guide decision-making for completing the vaccine series. We conducted a comprehensive review of the evidence on the safety, immunogenicity, efficacy, and effectiveness of the birth dose and a delayed first dose, and of the potential role of serology for clinical decision-making. We analyzed studies of the epidemiology of HBV infection, clinical trials, systematic reviews, vaccine safety from surveillance and clinical studies, and the potential impact of revised guidelines on individual and public health. We synthesized the history of ACIP recommendations and resulting trends in HBV incidence. The review found strong evidence for the safety and effectiveness of the birth dose, and no improvement in safety or effectiveness with a delayed first dose. We found no evidence to support the use of postvaccination serology. Infant vaccination has resulted in a 99% reduction in pediatric HBV infections; we found no evidence to support a change in vaccine recommendations but identified potential health consequences. 25:[[["$","script","0",{"type":"application/ld+json","dangerouslySetInnerHTML":{"__html":"{\"@context\":\"https://schema.org\",\"@type\":\"CollectionPage\",\"name\":\"Systematic Review / Narrative Review: study design Research & Clinical Takeaways\",\"description\":\"Explore peer-reviewed papers on Systematic Review / Narrative Review (study design). Clinician-written summaries and actionable practice insights. Updated daily.\",\"url\":\"https://www.reachrx.ai/hub/tag/study_design/Systematic%20Review%20%2F%20Narrative%20Review\",\"breadcrumb\":{\"@type\":\"BreadcrumbList\",\"itemListElement\":[{\"@type\":\"ListItem\",\"position\":1,\"name\":\"Home\",\"item\":\"https://www.reachrx.ai\"},{\"@type\":\"ListItem\",\"position\":2,\"name\":\"Research Hub\",\"item\":\"https://www.reachrx.ai/hub\"},{\"@type\":\"ListItem\",\"position\":3,\"name\":\"Study Designs\",\"item\":\"https://www.reachrx.ai/hub/tag/study_design\"},{\"@type\":\"ListItem\",\"position\":4,\"name\":\"Systematic Review / Narrative Review\",\"item\":\"https://www.reachrx.ai/hub/tag/study_design/Systematic%20Review%20%2F%20Narrative%20Review\"}]}}"}}]],["$","$L2f",null,{"title":"Systematic Review / Narrative Review: Research & Clinical Takeaways","description":"Browse Systematic Review / Narrative Review research papers with clear, practical takeaways for your clinical practice.","papers":[{"doi":"10.1016/j.athoracsur.2026.08.016","pmid":"42716272","title":"Emerging Longer-Term Evidence on Transcatheter Aortic Valve Implantation for Severe Aortic Stenosis in Low-Risk Patients: A Call for Caution","journal_title":"The Annals of Thoracic Surgery","journal_issn":"0003-4975","published_at":"2026-09-09T00:00:00.000Z","url":"https://doi.org/10.1016/j.athoracsur.2026.08.016","source_score":6,"is_retracted":false,"is_open_access":false,"raw_metadata":{"pubmed":true,"crossref":true,"unpaywall":true},"created_at":"2026-09-15T06:17:43.644Z","updated_at":"2026-09-15T06:17:43.644Z","tags":[{"paper_doi":"10.1016/j.athoracsur.2026.08.016","tag_type":"age_group","value":"adult","value_numeric":null},{"paper_doi":"10.1016/j.athoracsur.2026.08.016","tag_type":"age_group","value":"older_adult","value_numeric":null},{"paper_doi":"10.1016/j.athoracsur.2026.08.016","tag_type":"brand","value":"Evolut","value_numeric":null},{"paper_doi":"10.1016/j.athoracsur.2026.08.016","tag_type":"category","value":"Respiratory System","value_numeric":null},{"paper_doi":"10.1016/j.athoracsur.2026.08.016","tag_type":"condition","value":"Severe Aortic Stenosis","value_numeric":null},{"paper_doi":"10.1016/j.athoracsur.2026.08.016","tag_type":"impact_flag","value":"safety_signal","value_numeric":null},{"paper_doi":"10.1016/j.athoracsur.2026.08.016","tag_type":"level_of_evidence","value":"3","value_numeric":null},{"paper_doi":"10.1016/j.athoracsur.2026.08.016","tag_type":"modality","value":"Surgical Aortic Valve Replacement","value_numeric":null},{"paper_doi":"10.1016/j.athoracsur.2026.08.016","tag_type":"modality","value":"Transcatheter Aortic Valve Implantation","value_numeric":null},{"paper_doi":"10.1016/j.athoracsur.2026.08.016","tag_type":"sex","value":"mixed","value_numeric":null},{"paper_doi":"10.1016/j.athoracsur.2026.08.016","tag_type":"study_design","value":"Systematic Review / Narrative Review","value_numeric":null},{"paper_doi":"10.1016/j.athoracsur.2026.08.016","tag_type":"warning","value":"No aggregate sample size is reported across the reviewed studies; a sample_size tag was omitted.","value_numeric":null},{"paper_doi":"10.1016/j.athoracsur.2026.08.016","tag_type":"warning","value":"Study design is hybrid (narrative review plus meta-analysis and observational data synthesis); classified as Systematic/Narrative Review pending clearer methodological disclosure.","value_numeric":null},{"paper_doi":"10.1016/j.athoracsur.2026.08.016","tag_type":"warning","value":"The PARTNER 3 7-year findings are characterized by the authors as methodologically limited; clinicians should interpret those results with caution.","value_numeric":null},{"paper_doi":"10.1016/j.athoracsur.2026.08.016","tag_type":"warning","value":"This is a narrative/opinion review rather than a primary meta-analysis with pooled statistics; conclusions reflect the authors' interpretation of heterogeneous trial data. Level of evidence is estimated accordingly.","value_numeric":null}],"summaries":{"what_studied":"This review evaluates extended follow-up data (6–10 years) from pivotal TAVI vs. SAVR trials (Evolut Low Risk, PARTNER 3, PARTNER 2A, UK-TAVI) and meta-analyses to assess valve durability, late adverse events, and reintervention burden in low- and intermediate-risk patients with severe aortic stenosis.","key_result":"Evolut Low Risk (6–7 yr) showed no significant difference in death or disabling stroke, but signals of later mortality accrual, more MI events, and higher aortic valve reintervention with TAVI emerged; PARTNER 2A (10 yr) showed lower survival and higher reintervention rates with TAVI vs. SAVR in intermediate-risk patients; PARTNER 3 (7 yr) results were limited by methodological concerns.","limitations":"PARTNER 3 7-year data are constrained by non-prespecified hierarchical analysis, heterogeneous endpoint construction, incomplete follow-up, and post hoc vital-status ascertainment. Most pivotal trials underrepresent younger patients and anatomically complex cases. Long-term data beyond 10 years remain unavailable.","practice_takeaway":"For younger, low-risk patients with severe aortic stenosis, clinicians should exercise caution before defaulting to TAVI, explicitly discussing valve durability, reintervention options, and lifetime management within a structured Heart Team framework. SAVR may offer more durable outcomes at 10 years, particularly in intermediate-risk patients."}},{"doi":"10.1038/s41569-026-01342-3","pmid":"42687017","title":"Intracoronary imaging in percutaneous coronary intervention: why, when, how and which from large, randomized trials","journal_title":"Nature Reviews Cardiology","journal_issn":"1759-5002","published_at":"2026-09-02T00:00:00.000Z","url":"https://doi.org/10.1038/s41569-026-01342-3","source_score":28,"is_retracted":false,"is_open_access":false,"raw_metadata":{"pubmed":true,"crossref":true,"unpaywall":true},"created_at":"2026-09-09T06:21:08.719Z","updated_at":"2026-09-09T06:21:08.719Z","tags":[{"paper_doi":"10.1038/s41569-026-01342-3","tag_type":"age_group","value":"adult","value_numeric":null},{"paper_doi":"10.1038/s41569-026-01342-3","tag_type":"category","value":"Cardiac & Cardiovascular Systems","value_numeric":null},{"paper_doi":"10.1038/s41569-026-01342-3","tag_type":"condition","value":"Atherosclerosis","value_numeric":null},{"paper_doi":"10.1038/s41569-026-01342-3","tag_type":"condition","value":"Coronary Artery Disease","value_numeric":null},{"paper_doi":"10.1038/s41569-026-01342-3","tag_type":"impact_flag","value":"practice_changing","value_numeric":null},{"paper_doi":"10.1038/s41569-026-01342-3","tag_type":"level_of_evidence","value":"2","value_numeric":null},{"paper_doi":"10.1038/s41569-026-01342-3","tag_type":"modality","value":"Intracoronary Imaging","value_numeric":null},{"paper_doi":"10.1038/s41569-026-01342-3","tag_type":"modality","value":"Intravascular Ultrasound","value_numeric":null},{"paper_doi":"10.1038/s41569-026-01342-3","tag_type":"modality","value":"Optical Coherence Tomography","value_numeric":null},{"paper_doi":"10.1038/s41569-026-01342-3","tag_type":"modality","value":"Percutaneous Coronary Intervention","value_numeric":null},{"paper_doi":"10.1038/s41569-026-01342-3","tag_type":"sex","value":"mixed","value_numeric":null},{"paper_doi":"10.1038/s41569-026-01342-3","tag_type":"study_design","value":"Systematic Review / Narrative Review","value_numeric":null},{"paper_doi":"10.1038/s41569-026-01342-3","tag_type":"warning","value":"Full page content was not extracted from the PDF — only the abstract and metadata were available. Summary details are based solely on the abstract; specific event rates, hazard ratios, and per-trial results could not be verified from the full text.","value_numeric":null},{"paper_doi":"10.1038/s41569-026-01342-3","tag_type":"warning","value":"Study design tagged as 'Systematic Review / Narrative Review' based on abstract framing; the paper is described as a 'Review' synthesizing RCT evidence rather than a formal meta-analysis.","value_numeric":null},{"paper_doi":"10.1038/s41569-026-01342-3","tag_type":"warning","value":"The 'practice_changing' impact flag reflects the synthesis of eight large RCTs and the authors' stated aim of reshaping clinical decision-making for ICI use in PCI; individual trial results were mixed.","value_numeric":null}],"summaries":{"what_studied":"This review evaluates the clinical use of intracoronary imaging (ICI) — specifically IVUS and OCT — to guide percutaneous coronary intervention (PCI) in patients with coronary artery disease, synthesizing findings from eight large (n > 1,000) international randomized trials: ILUMIEN IV, IVUS-ACS, IVUS-CHIP, IVUS-XPL, OCCUPI, OCTOBER, RENOVATE-COMPLEX-PCI, and ULTIMATE.","key_result":"Across eight large randomized trials, ICI-guided PCI generally improved clinical outcomes compared with angiography-guided PCI, though results were heterogeneous; benefits were most consistent in complex lesion subsets and high-risk populations, while routine use in all-comers showed mixed findings.","limitations":"- Full text page content was not extractable, limiting granular data verification (e.g., absolute event rates per trial).\n- Heterogeneity in study populations and lack of standardized ICI optimization criteria across trials complicates cross-trial comparisons.\n- Mixed trial results leave uncertainty about which specific patient or lesion subgroups benefit most from ICI guidance in real-world practice.","practice_takeaway":"Clinicians should prioritize ICI guidance — IVUS or OCT — for complex PCI cases (e.g., ACS, calcified or long lesions), where the evidence for outcome benefit is most consistent. Patient selection and standardized ICI protocols are key to translating trial benefits to everyday practice."}},{"doi":"10.1016/s2213-8587(26)00186-5","pmid":"42660161","title":"From adiposity to multisystem morbidity: the case for weight loss as disease modification","journal_title":"The Lancet Diabetes & Endocrinology","journal_issn":"2213-8587","published_at":"2026-08-28T00:00:00.000Z","url":"https://doi.org/10.1016/s2213-8587(26)00186-5","source_score":16,"is_retracted":false,"is_open_access":false,"raw_metadata":{"pubmed":true,"crossref":true,"unpaywall":true},"created_at":"2026-09-06T06:22:57.417Z","updated_at":"2026-09-06T06:22:57.417Z","tags":[{"paper_doi":"10.1016/s2213-8587(26)00186-5","tag_type":"age_group","value":"adult","value_numeric":null},{"paper_doi":"10.1016/s2213-8587(26)00186-5","tag_type":"brand","value":"Mounjaro","value_numeric":null},{"paper_doi":"10.1016/s2213-8587(26)00186-5","tag_type":"brand","value":"Ozempic","value_numeric":null},{"paper_doi":"10.1016/s2213-8587(26)00186-5","tag_type":"brand","value":"Wegovy","value_numeric":null},{"paper_doi":"10.1016/s2213-8587(26)00186-5","tag_type":"brand","value":"Zepbound","value_numeric":null},{"paper_doi":"10.1016/s2213-8587(26)00186-5","tag_type":"category","value":"Endocrinology & Metabolism","value_numeric":null},{"paper_doi":"10.1016/s2213-8587(26)00186-5","tag_type":"condition","value":"Depression","value_numeric":null},{"paper_doi":"10.1016/s2213-8587(26)00186-5","tag_type":"condition","value":"Heart Failure With Preserved Ejection Fraction","value_numeric":null},{"paper_doi":"10.1016/s2213-8587(26)00186-5","tag_type":"condition","value":"Metabolic Dysfunction-Associated Steatotic Liver Disease","value_numeric":null},{"paper_doi":"10.1016/s2213-8587(26)00186-5","tag_type":"condition","value":"Obesity","value_numeric":null},{"paper_doi":"10.1016/s2213-8587(26)00186-5","tag_type":"condition","value":"Obstructive Sleep Apnoea","value_numeric":null},{"paper_doi":"10.1016/s2213-8587(26)00186-5","tag_type":"condition","value":"Osteoarthritis","value_numeric":null},{"paper_doi":"10.1016/s2213-8587(26)00186-5","tag_type":"condition","value":"Type 2 Diabetes","value_numeric":null},{"paper_doi":"10.1016/s2213-8587(26)00186-5","tag_type":"generic","value":"semaglutide","value_numeric":null},{"paper_doi":"10.1016/s2213-8587(26)00186-5","tag_type":"generic","value":"tirzepatide","value_numeric":null},{"paper_doi":"10.1016/s2213-8587(26)00186-5","tag_type":"impact_flag","value":"practice_changing","value_numeric":null},{"paper_doi":"10.1016/s2213-8587(26)00186-5","tag_type":"level_of_evidence","value":"2","value_numeric":null},{"paper_doi":"10.1016/s2213-8587(26)00186-5","tag_type":"modality","value":"GLP-1/GIP Dual Receptor Agonist","value_numeric":null},{"paper_doi":"10.1016/s2213-8587(26)00186-5","tag_type":"modality","value":"GLP-1 Receptor Agonist","value_numeric":null},{"paper_doi":"10.1016/s2213-8587(26)00186-5","tag_type":"modality","value":"Weight Loss Intervention","value_numeric":null},{"paper_doi":"10.1016/s2213-8587(26)00186-5","tag_type":"sex","value":"mixed","value_numeric":null},{"paper_doi":"10.1016/s2213-8587(26)00186-5","tag_type":"study_design","value":"Systematic Review / Narrative Review","value_numeric":null},{"paper_doi":"10.1016/s2213-8587(26)00186-5","tag_type":"warning","value":"Brand name tags (Ozempic, Wegovy, Mounjaro, Zepbound) are inferred from the generic drug names semaglutide and tirzepatide as used in obesity/diabetes contexts; the paper does not explicitly list brand names.","value_numeric":null},{"paper_doi":"10.1016/s2213-8587(26)00186-5","tag_type":"warning","value":"No specific sample size is reported, as this is a review article synthesising across multiple studies.","value_numeric":null},{"paper_doi":"10.1016/s2213-8587(26)00186-5","tag_type":"warning","value":"The paper is a narrative review using a triangulation framework — not a formal systematic review or meta-analysis — so the strength of causal inference varies by condition and evidence type.","value_numeric":null},{"paper_doi":"10.1016/s2213-8587(26)00186-5","tag_type":"warning","value":"The study design label 'Systematic Review / Narrative Review' reflects a hybrid approach; the authors describe triangulation of multiple evidence types rather than a preregistered systematic methodology.","value_numeric":null}],"summaries":{"what_studied":"This review evaluates whether weight-loss interventions (lifestyle, surgical, and pharmacological — notably semaglutide and tirzepatide) can prevent or modify common obesity-related conditions across musculoskeletal, metabolic, cardiovascular, mental health, respiratory, and hepatic domains, using a triangulation framework of epidemiological, genetic (including Mendelian randomisation), and randomised trial evidence.","key_result":"Robust trial evidence supports weight loss as disease-modifying in type 2 diabetes and heart failure with preserved ejection fraction; incretin-based therapies (semaglutide, tirzepatide) now achieve ~14–20% average weight loss in people without diabetes and have generated the first large-scale randomised evidence of disease modification across several conditions, though many areas (musculoskeletal, respiratory, mental health, cardiovascular) remain under-investigated.","limitations":"- Many conditions lack adequate randomised trial evidence, limiting causal conclusions.\n- Evidence on varying magnitudes of weight loss with different agents, disease-stage effects, and long-term (legacy) outcomes is sparse.\n- Trials have not adequately addressed multimorbidity, mechanistic mediation, diverse global populations, or access equity.","practice_takeaway":"Clinicians have strong evidence to use weight-loss therapies — especially GLP-1 receptor agonists like semaglutide and dual GLP-1/GIP agonists like tirzepatide — for disease modification in type 2 diabetes and HFpEF, but should recognise that evidence for many other obesity-related conditions is still emerging. Individualised treatment targets and long-term follow-up remain important given persistent gaps in outcome data."}},{"doi":"10.1111/apt.70920","pmid":"42596026","title":"Review Article: Immune Effector Cell‐Mediated Enterocolitis Following\n CAR\n ‐T Cell Therapy—Clinical Features, Pathophysiology and Management","journal_title":"Alimentary Pharmacology & Therapeutics","journal_issn":"0269-2813","published_at":"2026-08-13T00:00:00.000Z","url":"https://doi.org/10.1111/apt.70920","source_score":7,"is_retracted":false,"is_open_access":false,"raw_metadata":{"pubmed":true,"crossref":true,"unpaywall":true},"created_at":"2026-08-17T13:33:28.265Z","updated_at":"2026-08-17T13:33:28.265Z","tags":[{"paper_doi":"10.1111/apt.70920","tag_type":"age_group","value":"mixed","value_numeric":null},{"paper_doi":"10.1111/apt.70920","tag_type":"category","value":"Gastroenterology & Hepatology","value_numeric":null},{"paper_doi":"10.1111/apt.70920","tag_type":"condition","value":"Autoimmune Disease","value_numeric":null},{"paper_doi":"10.1111/apt.70920","tag_type":"condition","value":"Hematologic Malignancies","value_numeric":null},{"paper_doi":"10.1111/apt.70920","tag_type":"condition","value":"Immune Effector Cell-Mediated Enterocolitis","value_numeric":null},{"paper_doi":"10.1111/apt.70920","tag_type":"impact_flag","value":"safety_signal","value_numeric":null},{"paper_doi":"10.1111/apt.70920","tag_type":"level_of_evidence","value":"5","value_numeric":null},{"paper_doi":"10.1111/apt.70920","tag_type":"modality","value":"Biologic Therapy","value_numeric":null},{"paper_doi":"10.1111/apt.70920","tag_type":"modality","value":"CAR-T Cell Therapy","value_numeric":null},{"paper_doi":"10.1111/apt.70920","tag_type":"modality","value":"Small Molecule Therapy","value_numeric":null},{"paper_doi":"10.1111/apt.70920","tag_type":"sex","value":"mixed","value_numeric":null},{"paper_doi":"10.1111/apt.70920","tag_type":"study_design","value":"Systematic Review / Narrative Review","value_numeric":null},{"paper_doi":"10.1111/apt.70920","tag_type":"warning","value":"No sample size tag applied as the review aggregates across multiple case series without reporting a single pooled N.","value_numeric":null},{"paper_doi":"10.1111/apt.70920","tag_type":"warning","value":"The ~6% incidence figure is an upper estimate drawn from case series and may not reflect real-world rates across all CAR-T targets or centers.","value_numeric":null},{"paper_doi":"10.1111/apt.70920","tag_type":"warning","value":"The review mentions expanding CAR-T use in autoimmune diseases, but most IEC-EC data appear to derive from oncology (BCMA-targeted) populations — generalizability to autoimmune indications is uncertain.","value_numeric":null},{"paper_doi":"10.1111/apt.70920","tag_type":"warning","value":"This is a narrative/comprehensive review of case series, not a systematic review with meta-analysis; the evidence base is low quality and subject to publication bias.","value_numeric":null}],"summaries":{"what_studied":"This state-of-the-art review synthesizes all published case series on immune effector cell-mediated enterocolitis (IEC-EC), a rare gastrointestinal toxicity of CAR-T cell therapy, covering its epidemiology, pathophysiology, clinical features, endoscopic/histopathologic findings, and management strategies.","key_result":"IEC-EC occurs in up to ~6% of patients, most commonly after B cell maturation antigen (BCMA)-targeted CAR-T therapy; it presents with severe diarrhea and malabsorption, responds poorly to treatment, and carries a poor prognosis.","limitations":"Review is limited to case series data, which are inherently small and retrospective; no controlled trials exist. The true incidence may be underestimated due to underreporting and inconsistent recognition of IEC-EC across centers.","practice_takeaway":"Maintain a high index of suspicion for IEC-EC in any patient with GI symptoms after CAR-T therapy, especially BCMA-targeted regimens. Early multi-disciplinary management—including infection workup and step-up therapy with IBD biologics or small molecules—is recommended to improve outcomes."}},{"doi":"10.1097/moh.0000000000000948","pmid":"42593279","title":"Maintenance therapy after allogeneic stem cell transplantation for relapse prevention in myeloid malignancies","journal_title":"Current Opinion in Hematology","journal_issn":"1065-6251","published_at":"2026-08-13T00:00:00.000Z","url":"https://doi.org/10.1097/moh.0000000000000948","source_score":7,"is_retracted":false,"is_open_access":false,"raw_metadata":{"pubmed":true,"crossref":true,"unpaywall":true},"created_at":"2026-08-22T06:53:31.683Z","updated_at":"2026-08-22T06:53:31.683Z","tags":[{"paper_doi":"10.1097/moh.0000000000000948","tag_type":"age_group","value":"adult","value_numeric":null},{"paper_doi":"10.1097/moh.0000000000000948","tag_type":"brand","value":"Xospata","value_numeric":null},{"paper_doi":"10.1097/moh.0000000000000948","tag_type":"category","value":"Hematology","value_numeric":null},{"paper_doi":"10.1097/moh.0000000000000948","tag_type":"condition","value":"Acute Myeloid Leukemia","value_numeric":null},{"paper_doi":"10.1097/moh.0000000000000948","tag_type":"condition","value":"Myelodysplastic Syndromes","value_numeric":null},{"paper_doi":"10.1097/moh.0000000000000948","tag_type":"generic","value":"gilteritinib","value_numeric":null},{"paper_doi":"10.1097/moh.0000000000000948","tag_type":"generic","value":"sorafenib","value_numeric":null},{"paper_doi":"10.1097/moh.0000000000000948","tag_type":"impact_flag","value":"practice_changing","value_numeric":null},{"paper_doi":"10.1097/moh.0000000000000948","tag_type":"level_of_evidence","value":"5","value_numeric":null},{"paper_doi":"10.1097/moh.0000000000000948","tag_type":"modality","value":"Allogeneic Hematopoietic Cell Transplantation","value_numeric":null},{"paper_doi":"10.1097/moh.0000000000000948","tag_type":"modality","value":"FLT3 Inhibitor","value_numeric":null},{"paper_doi":"10.1097/moh.0000000000000948","tag_type":"modality","value":"Hypomethylating Agent","value_numeric":null},{"paper_doi":"10.1097/moh.0000000000000948","tag_type":"modality","value":"IDH Inhibitor","value_numeric":null},{"paper_doi":"10.1097/moh.0000000000000948","tag_type":"modality","value":"Menin Inhibitor","value_numeric":null},{"paper_doi":"10.1097/moh.0000000000000948","tag_type":"study_design","value":"Systematic Review / Narrative Review","value_numeric":null},{"paper_doi":"10.1097/moh.0000000000000948","tag_type":"warning","value":"Sample size tag was omitted as this is a review article with no single study population.","value_numeric":null},{"paper_doi":"10.1097/moh.0000000000000948","tag_type":"warning","value":"Sex distribution of patient populations across reviewed trials is not reported in the abstract; sex tag was omitted.","value_numeric":null},{"paper_doi":"10.1097/moh.0000000000000948","tag_type":"warning","value":"The impact_flag 'practice_changing' reflects the shift toward MRD-guided targeted strategies described in the review, but most supporting data come from individual trials cited within, not from this review itself.","value_numeric":null},{"paper_doi":"10.1097/moh.0000000000000948","tag_type":"warning","value":"This is a narrative/critical review, not a primary study or meta-analysis — evidence levels vary by agent discussed within the paper.","value_numeric":null}],"summaries":{"what_studied":"This review evaluates the evidence for post-allogeneic HCT maintenance therapy to prevent relapse in AML and MDS, covering FLT3 inhibitors, IDH inhibitors, menin inhibitors, and hypomethylating agents, with attention to MRD-guided patient selection strategies.","key_result":"FLT3 inhibitors (sorafenib, gilteritinib) have the strongest evidence from randomized trials in FLT3-ITD AML; the MORPHO trial showed MRD status identifies patients most likely to benefit from gilteritinib. IDH and menin inhibitors are promising but lack randomized data. Hypomethylating agent maintenance yielded inconsistent results, with evidence favoring MRD-triggered preemptive therapy over broad application.","limitations":"No large, adequately powered HCT-specific randomized trials exist for most agents; MRD endpoints lack standardization across studies; evidence for IDH inhibitors and menin inhibitors is limited to non-randomized data.","practice_takeaway":"For FLT3-ITD AML post-HCT, consider sorafenib or gilteritinib maintenance, using MRD status to guide patient selection. For patients without actionable mutations, MRD-triggered preemptive therapy is preferred over routine hypomethylating agent maintenance."}},{"doi":"10.1007/s00125-026-06811-5","pmid":"42502137","title":"Non-pharmacological treatment of MASLD","journal_title":"Diabetologia","journal_issn":"0012-186X","published_at":"2026-07-25T00:00:00.000Z","url":"https://doi.org/10.1007/s00125-026-06811-5","source_score":10,"is_retracted":false,"is_open_access":true,"raw_metadata":{"pubmed":true,"crossref":true,"unpaywall":true},"created_at":"2026-07-31T13:36:50.864Z","updated_at":"2026-07-31T13:36:50.864Z","tags":[{"paper_doi":"10.1007/s00125-026-06811-5","tag_type":"age_group","value":"adult","value_numeric":null},{"paper_doi":"10.1007/s00125-026-06811-5","tag_type":"category","value":"Endocrinology & Metabolism","value_numeric":null},{"paper_doi":"10.1007/s00125-026-06811-5","tag_type":"condition","value":"Hepatic Steatosis","value_numeric":null},{"paper_doi":"10.1007/s00125-026-06811-5","tag_type":"condition","value":"Hepatocellular Carcinoma","value_numeric":null},{"paper_doi":"10.1007/s00125-026-06811-5","tag_type":"condition","value":"Metabolic Dysfunction-Associated Steatotic Liver Disease","value_numeric":null},{"paper_doi":"10.1007/s00125-026-06811-5","tag_type":"condition","value":"Type 2 Diabetes","value_numeric":null},{"paper_doi":"10.1007/s00125-026-06811-5","tag_type":"impact_flag","value":"confirms_prior","value_numeric":null},{"paper_doi":"10.1007/s00125-026-06811-5","tag_type":"level_of_evidence","value":"3","value_numeric":null},{"paper_doi":"10.1007/s00125-026-06811-5","tag_type":"modality","value":"Aerobic Exercise","value_numeric":null},{"paper_doi":"10.1007/s00125-026-06811-5","tag_type":"modality","value":"Dietary Modification","value_numeric":null},{"paper_doi":"10.1007/s00125-026-06811-5","tag_type":"modality","value":"High-Intensity Interval Training","value_numeric":null},{"paper_doi":"10.1007/s00125-026-06811-5","tag_type":"modality","value":"Lifestyle Intervention","value_numeric":null},{"paper_doi":"10.1007/s00125-026-06811-5","tag_type":"modality","value":"Resistance Training","value_numeric":null},{"paper_doi":"10.1007/s00125-026-06811-5","tag_type":"sex","value":"mixed","value_numeric":null},{"paper_doi":"10.1007/s00125-026-06811-5","tag_type":"study_design","value":"Systematic Review / Narrative Review","value_numeric":null},{"paper_doi":"10.1007/s00125-026-06811-5","tag_type":"warning","value":"Many cited meta-analyses used older NAFLD/NASH nomenclature rather than MASLD, which may reflect heterogeneous patient populations.","value_numeric":null},{"paper_doi":"10.1007/s00125-026-06811-5","tag_type":"warning","value":"Sample size cannot be determined from the provided content; tag omitted.","value_numeric":null},{"paper_doi":"10.1007/s00125-026-06811-5","tag_type":"warning","value":"Study design classification is ambiguous: the abstract describes a narrative review, but the supplementary material summarises findings from systematic reviews and meta-analyses; tagged as Systematic Review / Narrative Review accordingly.","value_numeric":null},{"paper_doi":"10.1007/s00125-026-06811-5","tag_type":"warning","value":"The full text provided is only the supplementary table (ESM Table 1) with its references, not the complete review article body — key result data are drawn from cited meta-analyses, not primary study data collected by the authors.","value_numeric":null}],"summaries":{"what_studied":"This review examines the evidence for non-pharmacological (lifestyle) interventions in MASLD, covering dietary modification, physical activity/exercise, sleep, and circadian rhythm changes, with a focus on weight loss strategies and their effects on hepatic and cardiometabolic outcomes.","key_result":"Combined diet and exercise yields the largest improvements: ALT reduction (MD −13.27), HOMA-IR reduction (MD −2.07), and ~50% intrahepatic lipid (IHL) reduction vs ~30% with exercise alone. Aerobic exercise alone reduced IHL (SMD −0.98). Exercise shows a dose-dependent reduction in risk of hepatic steatosis, fibrosis, and hepatocellular carcinoma.","limitations":"- Long-term adherence to lifestyle changes is suboptimal, limiting durability of benefits.\n- Significant individual variability in treatment response; validated biomarkers for personalised approaches are lacking.\n- Evidence is largely based on prior systematic reviews and meta-analyses of heterogeneous trials (many using older NAFLD nomenclature), which may affect precision of effect estimates.","practice_takeaway":"Combine energy-restricted diet with regular exercise for the greatest liver and metabolic benefit in MASLD — even modest weight loss helps. Exercise reduces liver fat partly independent of weight loss, so it should be prescribed regardless of scale results."}},{"doi":"10.1093/ndt/gfag155","pmid":"42397131","title":"Pivotal Clinical Trials in C3 Glomerulopathy: answers and remaining uncertainties","journal_title":"Nephrology Dialysis Transplantation","journal_issn":"0931-0509","published_at":"2026-07-03T00:00:00.000Z","url":"https://doi.org/10.1093/ndt/gfag155","source_score":8,"is_retracted":false,"is_open_access":true,"raw_metadata":{"pubmed":true,"crossref":true,"unpaywall":true},"created_at":"2026-07-06T13:36:19.030Z","updated_at":"2026-07-06T13:36:19.030Z","tags":[{"paper_doi":"10.1093/ndt/gfag155","tag_type":"age_group","value":"mixed","value_numeric":null},{"paper_doi":"10.1093/ndt/gfag155","tag_type":"category","value":"Urology & Nephrology","value_numeric":null},{"paper_doi":"10.1093/ndt/gfag155","tag_type":"condition","value":"C3 Glomerulopathy","value_numeric":null},{"paper_doi":"10.1093/ndt/gfag155","tag_type":"condition","value":"Immune Complex-Mediated Membranoproliferative Glomerulonephritis","value_numeric":null},{"paper_doi":"10.1093/ndt/gfag155","tag_type":"condition","value":"Membranoproliferative Glomerulonephritis","value_numeric":null},{"paper_doi":"10.1093/ndt/gfag155","tag_type":"generic","value":"iptacopan","value_numeric":null},{"paper_doi":"10.1093/ndt/gfag155","tag_type":"generic","value":"pegcetacoplan","value_numeric":null},{"paper_doi":"10.1093/ndt/gfag155","tag_type":"impact_flag","value":"practice_changing","value_numeric":null},{"paper_doi":"10.1093/ndt/gfag155","tag_type":"level_of_evidence","value":"3","value_numeric":null},{"paper_doi":"10.1093/ndt/gfag155","tag_type":"modality","value":"C3 Inhibitor","value_numeric":null},{"paper_doi":"10.1093/ndt/gfag155","tag_type":"modality","value":"Complement Inhibitor","value_numeric":null},{"paper_doi":"10.1093/ndt/gfag155","tag_type":"modality","value":"Factor B Inhibitor","value_numeric":null},{"paper_doi":"10.1093/ndt/gfag155","tag_type":"study_design","value":"Systematic Review / Narrative Review","value_numeric":null},{"paper_doi":"10.1093/ndt/gfag155","tag_type":"warning","value":"Age group tagged as 'mixed' as the abstract does not specify a particular age population for the reviewed trials.","value_numeric":null},{"paper_doi":"10.1093/ndt/gfag155","tag_type":"warning","value":"Level of evidence assigned as 3 (reflecting a critical appraisal of phase 3 RCTs), but the article itself is a review article; the underlying trials are level 1.","value_numeric":null},{"paper_doi":"10.1093/ndt/gfag155","tag_type":"warning","value":"This is a narrative/critical review, not a primary trial report — no sample size or direct trial data are reported within the abstract itself.","value_numeric":null}],"summaries":{"what_studied":"This review critically appraises pivotal phase 3 trials of two proximal complement inhibitors — iptacopan (factor B inhibitor) and pegcetacoplan (C3 inhibitor) — for C3 glomerulopathy (C3G) and primary IC-MPGN, ultra-rare complement-driven glomerular diseases.","key_result":"Both iptacopan and pegcetacoplan demonstrated clinically meaningful reductions in proteinuria and stabilization of kidney function in their respective phase 3 trials, establishing proof of efficacy for targeted complement inhibition in C3G/IC-MPGN.","limitations":"- No validated biomarkers exist to guide patient selection or monitor complement blockade.\n- Long-term kidney outcomes, optimal treatment duration/sequencing, and discontinuation strategies remain unresolved.\n- Real-world data and pragmatic evidence for special populations and health-system implementation are lacking.","practice_takeaway":"Clinicians now have two phase 3-supported complement inhibitors for C3G and IC-MPGN, but should recognize that optimal patient selection, treatment timing, and monitoring protocols are still undefined. Awaiting long-term outcome data before broadly standardizing therapy is prudent."}},{"doi":"10.1007/s00125-026-06785-4","pmid":"42362970","title":"SARS-CoV-2 and diabetes: a post-pandemic reappraisal","journal_title":"Diabetologia","journal_issn":"0012-186X","published_at":"2026-06-27T00:00:00.000Z","url":"https://doi.org/10.1007/s00125-026-06785-4","source_score":27,"is_retracted":false,"is_open_access":true,"raw_metadata":{"pubmed":true,"crossref":true,"unpaywall":true},"created_at":"2026-07-04T13:26:20.515Z","updated_at":"2026-07-04T13:26:20.515Z","tags":[{"paper_doi":"10.1007/s00125-026-06785-4","tag_type":"age_group","value":"mixed","value_numeric":null},{"paper_doi":"10.1007/s00125-026-06785-4","tag_type":"category","value":"Endocrinology & Metabolism","value_numeric":null},{"paper_doi":"10.1007/s00125-026-06785-4","tag_type":"condition","value":"COVID-19","value_numeric":null},{"paper_doi":"10.1007/s00125-026-06785-4","tag_type":"condition","value":"Long COVID","value_numeric":null},{"paper_doi":"10.1007/s00125-026-06785-4","tag_type":"condition","value":"Type 1 Diabetes","value_numeric":null},{"paper_doi":"10.1007/s00125-026-06785-4","tag_type":"condition","value":"Type 2 Diabetes","value_numeric":null},{"paper_doi":"10.1007/s00125-026-06785-4","tag_type":"generic","value":"SARS-CoV-2 vaccine","value_numeric":null},{"paper_doi":"10.1007/s00125-026-06785-4","tag_type":"impact_flag","value":"confirms_prior","value_numeric":null},{"paper_doi":"10.1007/s00125-026-06785-4","tag_type":"level_of_evidence","value":"3","value_numeric":null},{"paper_doi":"10.1007/s00125-026-06785-4","tag_type":"modality","value":"Vaccine","value_numeric":null},{"paper_doi":"10.1007/s00125-026-06785-4","tag_type":"study_design","value":"Systematic Review / Narrative Review","value_numeric":null},{"paper_doi":"10.1007/s00125-026-06785-4","tag_type":"warning","value":"No specific sample size is reported as this is a review article aggregating multiple studies.","value_numeric":null},{"paper_doi":"10.1007/s00125-026-06785-4","tag_type":"warning","value":"The study design label 'Systematic Review / Narrative Review' is approximate — the abstract describes it as a review with elements of both narrative synthesis and meta-analysis appraisal, but does not explicitly state a systematic methodology.","value_numeric":null},{"paper_doi":"10.1007/s00125-026-06785-4","tag_type":"warning","value":"This is a narrative/post-pandemic reappraisal review; it synthesizes heterogeneous evidence including meta-analyses and registry studies, so level of evidence reflects the review design rather than any single high-quality RCT.","value_numeric":null}],"summaries":{"what_studied":"This post-pandemic review evaluates the bidirectional relationship between SARS-CoV-2 infection and diabetes, covering pathophysiological mechanisms (pancreatic effects, insulin resistance), meta-analyses on incident type 1 and type 2 diabetes post-COVID-19, long COVID–diabetes links, and the impact of vaccination on diabetes risk.","key_result":"Diabetes was one of the strongest early predictors of severe COVID-19 outcomes and mortality; the review synthesizes evidence that SARS-CoV-2 infection may also trigger new-onset diabetes, though the strength and causality of this association vary by study quality, with prospective cohorts and registry studies providing the highest-quality data.","limitations":"- Underlying epidemiologic studies often relied on preliminary or conflicting evidence from early pandemic conditions.\n- Causality between SARS-CoV-2 infection and incident diabetes remains unresolved due to heterogeneity in study designs.\n- Critical knowledge gaps persist, particularly around long COVID and diabetes and the durability of vaccination's protective effect.","practice_takeaway":"Clinicians should monitor patients with a history of COVID-19 for new-onset diabetes, especially those with risk factors, and consider vaccination as a potential modifier of post-infection diabetes risk. Recognize that early pandemic data on COVID-19 severity in diabetes patients shaped care frameworks that may need reappraisal as higher-quality evidence matures."}},{"doi":"10.1182/blood.2025031651","pmid":"41779722","title":"Prognostic factors and progression biomarkers in AL amyloidosis: mapping current knowledge and critical gaps","journal_title":"Blood","journal_issn":"0006-4971","published_at":"2026-03-04T00:00:00.000Z","url":"https://doi.org/10.1182/blood.2025031651","source_score":17,"is_retracted":false,"is_open_access":true,"raw_metadata":{"pubmed":true,"crossref":true,"unpaywall":true},"created_at":"2026-05-26T13:35:15.432Z","updated_at":"2026-05-26T13:35:15.432Z","tags":[{"paper_doi":"10.1182/blood.2025031651","tag_type":"age_group","value":"adult","value_numeric":null},{"paper_doi":"10.1182/blood.2025031651","tag_type":"brand","value":"Darzalex","value_numeric":null},{"paper_doi":"10.1182/blood.2025031651","tag_type":"category","value":"Hematology","value_numeric":null},{"paper_doi":"10.1182/blood.2025031651","tag_type":"condition","value":"AL Amyloidosis","value_numeric":null},{"paper_doi":"10.1182/blood.2025031651","tag_type":"condition","value":"Systemic Immunoglobulin Light Chain Amyloidosis","value_numeric":null},{"paper_doi":"10.1182/blood.2025031651","tag_type":"generic","value":"daratumumab","value_numeric":null},{"paper_doi":"10.1182/blood.2025031651","tag_type":"impact_flag","value":"practice_changing","value_numeric":null},{"paper_doi":"10.1182/blood.2025031651","tag_type":"level_of_evidence","value":"5","value_numeric":null},{"paper_doi":"10.1182/blood.2025031651","tag_type":"modality","value":"Anti-CD38 Monoclonal Antibody","value_numeric":null},{"paper_doi":"10.1182/blood.2025031651","tag_type":"modality","value":"Biomarker / Prognostic Model","value_numeric":null},{"paper_doi":"10.1182/blood.2025031651","tag_type":"study_design","value":"Systematic Review / Narrative Review","value_numeric":null},{"paper_doi":"10.1182/blood.2025031651","tag_type":"warning","value":"Publication date is listed as 2026-03-04, which is in the future relative to many referenced studies; cited trial data should be verified against primary sources.","value_numeric":null},{"paper_doi":"10.1182/blood.2025031651","tag_type":"warning","value":"Study design is described as a 'comprehensive review' — it is not clear whether a formal systematic search methodology was used; tagged as Systematic/Narrative Review with uncertainty.","value_numeric":null},{"paper_doi":"10.1182/blood.2025031651","tag_type":"warning","value":"The ANDROMEDA trial 76% 5-year OS figure is cited as a benchmark but the review itself does not report new primary data.","value_numeric":null}],"summaries":{"what_studied":"This comprehensive review maps current prognostic factors and progression biomarkers in AL amyloidosis, categorizing them into disease-specific (clone- and organ-related) and patient-specific factors, with a focus on the gap between older risk models and outcomes under modern daratumumab-based regimens.","key_result":"Daratumumab-based regimens achieve 76% 5-year overall survival (ANDROMEDA trial). Traditional baseline biomarkers — difference between involved/uninvolved free light chains and bone marrow plasma cell burden — are losing prognostic value with effective clone-directed therapy. Emerging dynamic markers (MRD by free light chain mass spectrometry, cardiac global longitudinal strain) show promise.","limitations":"- Existing prognostic models were derived from populations treated with now-suboptimal regimens, limiting applicability to contemporary practice.\n- Validation studies for emerging biomarkers (e.g., FLC mass spectrometry, GLS) are still lacking.\n- As a review, it does not generate new primary outcome data.","practice_takeaway":"Clinicians should recognize that legacy staging systems may underestimate prognosis in patients receiving daratumumab-based therapy. Incorporating dynamic biomarkers like MRD and cardiac imaging (global longitudinal strain) into follow-up may better identify high-risk patients who need therapy beyond anti-plasma cell treatment."}},{"doi":"10.1542/peds.2025-075783","pmid":"41639943","title":"Hepatitis B Vaccination at Birth: Safety, Effectiveness, and Public Health Benefit","journal_title":"Pediatrics","journal_issn":"0031-4005","published_at":"2026-02-05T00:00:00.000Z","url":"https://doi.org/10.1542/peds.2025-075783","source_score":212,"is_retracted":false,"is_open_access":true,"raw_metadata":{"ooir":{"day":"2026-04-20","doi":"10.1542/peds.2025-075783","days":"30","issn":"0031-4005","rank":"4","field":"Clinical Medicine","score":"212","category":"Pediatrics","categories":["Pediatrics"],"_categories":["Pediatrics"]},"pubmed":{"doi":"10.1542/peds.2025-075783","title":"Hepatitis B Vaccination at Birth: Safety, Effectiveness, and Public Health Benefit.","journal":"Pediatrics","methods":"","results":"","abstract":"$30","keywords":[],"pubmed_id":"41639943","conclusions":"","publication_date":"2026-02-05T00:00:00"},"crossref":{"DOI":"10.1542/peds.2025-075783","URL":"https://doi.org/10.1542/peds.2025-075783","ISSN":["0031-4005","1098-4275"],"link":[{"URL":"https://publications.aap.org/pediatrics/article-pdf/doi/10.1542/peds.2025-075783/1926230/pediatrics.2025075783.pdf","content-type":"application/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"https://publications.aap.org/pediatrics/article-pdf/doi/10.1542/peds.2025-075783/1926230/pediatrics.2025075783.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"page":null,"type":"journal-article","issue":"5","score":1,"title":["Hepatitis B Vaccination at Birth: Safety, Effectiveness, and Public Health Benefit"],"author":[{"given":"Angela K.","family":"Ulrich","sequence":"first","affiliation":[{"name":"1Center for Infectious Disease Research and Policy (CIDRAP), University of Minnesota, Minneapolis, Minnesota"}]},{"given":"Derek F.","family":"Fleming","sequence":"additional","affiliation":[{"name":"1Center for Infectious Disease Research and Policy (CIDRAP), University of Minnesota, Minneapolis, Minnesota"}]},{"given":"Emily A.","family":"Smith","sequence":"additional","affiliation":[{"name":"1Center for Infectious Disease Research and Policy (CIDRAP), University of Minnesota, Minneapolis, Minnesota"}]},{"given":"Cory J.","family":"Anderson","sequence":"additional","affiliation":[{"name":"1Center for Infectious Disease Research and Policy (CIDRAP), University of Minnesota, Minneapolis, Minnesota"}]},{"given":"Angela J.","family":"Mehr","sequence":"additional","affiliation":[{"name":"1Center for Infectious Disease Research and Policy (CIDRAP), University of Minnesota, Minneapolis, Minnesota"}]},{"given":"Sydney G.","family":"Redepenning","sequence":"additional","affiliation":[{"name":"1Center for Infectious Disease Research and Policy (CIDRAP), University of Minnesota, Minneapolis, Minnesota"}]},{"given":"Clare J.","family":"Stoddart","sequence":"additional","affiliation":[{"name":"1Center for Infectious Disease Research and Policy (CIDRAP), University of Minnesota, Minneapolis, Minnesota"}]},{"given":"Leah E.","family":"Moat","sequence":"additional","affiliation":[{"name":"1Center for Infectious Disease Research and Policy (CIDRAP), University of Minnesota, Minneapolis, Minnesota"}]},{"given":"Rochelle P.","family":"Walensky","sequence":"additional","affiliation":[{"name":"2Division of General Internal Medicine and Infectious Disease, Massachusetts General Hospital, Harvard Medical School, Boston, Massachusetts"}]},{"given":"Eve M.","family":"Lackritz","sequence":"additional","affiliation":[{"name":"1Center for Infectious Disease Research and Policy (CIDRAP), University of Minnesota, Minneapolis, Minnesota"}]}],"issued":{"date-parts":[[2026,4,17]]},"member":"417","prefix":"10.1542","source":"Crossref","volume":"157","created":{"date-time":"2026-02-05T05:01:51Z","timestamp":1770267711000,"date-parts":[[2026,2,5]]},"indexed":{"date-time":"2026-05-12T16:15:12Z","timestamp":1778602512545,"date-parts":[[2026,5,12]]},"subject":[],"abstract":"$31","language":"en","relation":{},"resource":{"primary":{"URL":"https://publications.aap.org/pediatrics/article/157/5/e2025075783/206357/Hepatitis-B-Vaccination-at-Birth-Safety"}},"subtitle":[],"deposited":{"date-time":"2026-05-12T15:52:22Z","timestamp":1778601142000,"date-parts":[[2026,5,12]]},"issn-type":[{"type":"print","value":"0031-4005"},{"type":"electronic","value":"1098-4275"}],"published":{"date-parts":[[2026,4,17]]},"publisher":"American Academy of Pediatrics (AAP)","reference":[{"DOI":null,"key":"2026051211520698100_r1","year":"1991","issue":null,"author":"CDC","volume":null,"first-page":null,"unstructured":null,"article-title":"Hepatitis B Virus: A Comprehensive Strategy for Eliminating Transmission in the United States through Universal Childhood Vaccination: Recommendations of the Immunization Practices Advisory Committee (ACIP)","journal-title":null,"doi-asserted-by":null},{"DOI":null,"key":"2026051211520698100_r2","year":"2016","issue":null,"author":"HHS","volume":null,"first-page":null,"unstructured":null,"article-title":"Viral Hepatitis National Strategic Plan | HHS.Gov. Page","journal-title":null,"doi-asserted-by":null},{"DOI":"10.1098/rspb.1993.0102","key":"2026051211520698100_r3","year":"1993","issue":"1337","author":"Edmunds","volume":"253","first-page":"197","unstructured":null,"article-title":"The influence of age on the development of the hepatitis B carrier state","journal-title":"Proc Biol Sci.","doi-asserted-by":"crossref"},{"DOI":"10.1186/s12889-024-20462-4","key":"2026051211520698100_r4","year":"2024","issue":"1","author":"Li","volume":"24","first-page":"2936","unstructured":null,"article-title":"Global, regional, and national total burden related to hepatitis B in children and adolescents from 1990 to 2021","journal-title":"BMC Public Health.","doi-asserted-by":"crossref"},{"DOI":"10.1016/S0140-6736(83)90624-4","key":"2026051211520698100_r5","year":"1983","issue":"8359","author":"Beasley","volume":"2","first-page":"1099","unstructured":null,"article-title":"Prevention of perinatally transmitted hepatitis B virus infections with hepatitis B immune globulin and hepatitis B vaccine","journal-title":"Lancet.","doi-asserted-by":"crossref"},{"DOI":"10.1542/9781610025225","key":"2026051211520698100_r6","year":"2021","issue":null,"author":"Kimberlin","volume":null,"first-page":null,"unstructured":null,"article-title":null,"journal-title":null,"doi-asserted-by":"crossref"},{"DOI":"10.1001/jama.1995.03530150025029","key":"2026051211520698100_r7","year":"1995","issue":"15","author":"Margolis","volume":"274","first-page":"1201","unstructured":null,"article-title":"Prevention of hepatitis B virus transmission by immunization. An economic analysis of current recommendations","journal-title":"JAMA.","doi-asserted-by":"crossref"},{"DOI":"10.1093/jpids/piu064","key":"2026051211520698100_r8","year":"2014","issue":"Suppl 1","author":"Nelson","volume":"3","first-page":"S7","unstructured":null,"article-title":"Prevention of perinatal hepatitis B virus transmission","journal-title":"J Pediatric Infect Dis Soc.","doi-asserted-by":"crossref"},{"DOI":"10.1542/peds.2014-3213","key":"2026051211520698100_r9","year":"2015","issue":"5","author":"Schillie","volume":"135","first-page":"e1141","unstructured":null,"article-title":"Outcomes of infants born to women infected with hepatitis B","journal-title":"Pediatrics.","doi-asserted-by":"crossref"},{"DOI":"10.1542/peds.2017-1870","key":"2026051211520698100_r10","year":"2017","issue":"3","author":"Committee on Infectious Diseasescommittee on Fetus and Newborn","volume":"140","first-page":"e20171870","unstructured":null,"article-title":"Elimination of perinatal hepatitis B: providing the first vaccine dose within 24 hours of birth","journal-title":"Pediatrics.","doi-asserted-by":"crossref"},{"DOI":null,"key":"2026051211520698100_r11","year":"2025","issue":null,"author":"Drutz","volume":null,"first-page":null,"unstructured":null,"article-title":"Hepatitis B virus immunization in infants, children, and Adolescents - UpToDate","journal-title":null,"doi-asserted-by":null},{"DOI":"10.15585/mmwr.rr6701a1","key":"2026051211520698100_r12","year":"2018","issue":"1","author":"Schillie","volume":"67","first-page":"1","unstructured":null,"article-title":"Prevention of Hepatitis B virus infection in the United States: Recommendations of the Advisory Committee on Immunization Practices","journal-title":"MMWR Recomm Rep.","doi-asserted-by":"crossref"},{"DOI":null,"key":"2026051211520698100_r13","year":"2025","issue":null,"author":"CDC","volume":null,"first-page":null,"unstructured":null,"article-title":"ACIP Meeting Information","journal-title":null,"doi-asserted-by":null},{"DOI":null,"key":"2026051211520698100_r14","year":"2025","issue":null,"author":"CIDRAP","volume":null,"first-page":null,"unstructured":null,"article-title":"Universal hepatitis B vaccination at birth: safety, effectiveness, and public health impact","journal-title":null,"doi-asserted-by":null},{"DOI":null,"key":"2026051211520698100_r15","year":"2025","issue":null,"author":"Sekar","volume":null,"first-page":null,"unstructured":null,"article-title":"The Advisory Committee on Immunization Practices (ACIP)","journal-title":null,"doi-asserted-by":null},{"DOI":null,"key":"2026051211520698100_r16","year":"2014","issue":null,"author":"Smith","volume":null,"first-page":null,"unstructured":null,"article-title":"History and evolution of the Advisory Committee on Immunization Practices — United States, 1964–2014","journal-title":null,"doi-asserted-by":null},{"DOI":null,"key":"2026051211520698100_r17","year":"2025","issue":null,"author":"CDC","volume":null,"first-page":null,"unstructured":null,"article-title":"Grade Evidence Tables – Recommendations in MMWR","journal-title":null,"doi-asserted-by":null},{"DOI":"10.15585/mmwr.mm6745a4","key":"2026051211520698100_r18","year":"2018","issue":"45","author":"Lee","volume":"67","first-page":"1271","unstructured":null,"article-title":"Updated framework for development of evidence-based recommendations by the Advisory Committee on Immunization Practices","journal-title":"MMWR Morb Mortal Wkly Rep.","doi-asserted-by":"crossref"},{"DOI":null,"key":"2026051211520698100_r19","year":"2025","issue":null,"author":"CDC","volume":null,"first-page":null,"unstructured":null,"article-title":"Evidence to recommendations frameworks","journal-title":null,"doi-asserted-by":null},{"DOI":null,"key":"2026051211520698100_r20","year":"2019","issue":null,"author":"FDA","volume":null,"first-page":null,"unstructured":null,"article-title":"Recombivax HB","journal-title":null,"doi-asserted-by":null},{"DOI":null,"key":"2026051211520698100_r21","year":"2023","issue":null,"author":"Engerix-B FDA","volume":null,"first-page":null,"unstructured":null,"article-title":null,"journal-title":null,"doi-asserted-by":null},{"DOI":"10.1542/peds.108.5.1123","key":"2026051211520698100_r22","year":"2001","issue":"5","author":"Armstrong","volume":"108","first-page":"1123","unstructured":null,"article-title":"Childhood hepatitis B virus infections in the United States before hepatitis B immunization","journal-title":"Pediatrics.","doi-asserted-by":"crossref"},{"DOI":null,"key":"2026051211520698100_r23","year":"2024","issue":null,"author":"CDC","volume":null,"first-page":null,"unstructured":null,"article-title":null,"journal-title":null,"doi-asserted-by":null},{"DOI":null,"key":"2026051211520698100_r24","year":"2025","issue":null,"author":"CDC","volume":null,"first-page":null,"unstructured":null,"article-title":null,"journal-title":null,"doi-asserted-by":null},{"DOI":null,"key":"2026051211520698100_r25","year":"2004","issue":null,"author":"CDC","volume":null,"first-page":null,"unstructured":null,"article-title":"Acute Hepatitis B among children and adolescents—United States, 1990–2002","journal-title":null,"doi-asserted-by":null},{"DOI":"10.1097/HC9.0000000000000118","key":"2026051211520698100_r26","year":"2023","issue":"4","author":"Bixler","volume":"7","first-page":"e0118","unstructured":null,"article-title":"Prevalence and awareness of Hepatitis B virus infection in the United States: January 2017 - March 2020","journal-title":"Hepatol Commun.","doi-asserted-by":"crossref"},{"DOI":null,"key":"2026051211520698100_r27","year":"2025","issue":null,"author":"CDC","volume":null,"first-page":null,"unstructured":null,"article-title":"NNDSS Annual Summary Data 2016–2022 Request","journal-title":null,"doi-asserted-by":null},{"DOI":null,"key":"2026051211520698100_r28","year":"2020","issue":"361","author":"Kruszon-Moran","volume":null,"first-page":"1","unstructured":null,"article-title":"Prevalence and trends in Hepatitis B virus infection in the United States, 2015–2018","journal-title":"NCHS Data Brief.","doi-asserted-by":null},{"DOI":"10.1002/hep.30831","key":"2026051211520698100_r29","year":"2020","issue":"2","author":"Le","volume":"71","first-page":"431","unstructured":null,"article-title":"Chronic hepatitis B prevalence among foreign-born and U.S.-born adults in the United States, 1999–2016","journal-title":"Hepatology.","doi-asserted-by":"crossref"},{"DOI":null,"key":"2026051211520698100_r30","year":"2025","issue":null,"author":"CDC","volume":null,"first-page":null,"unstructured":null,"article-title":null,"journal-title":null,"doi-asserted-by":null},{"DOI":"10.1016/j.ajog.2014.10.1093","key":"2026051211520698100_r31","year":"2015","issue":"4","author":"Ellington","volume":"212","first-page":"524","unstructured":null,"article-title":"Recent trends in hepatic diseases during pregnancy in the United States, 2002–2010","journal-title":"Am J Obstet Gynecol.","doi-asserted-by":"crossref"},{"DOI":null,"key":"2026051211520698100_r32","year":"2018","issue":"1","author":"Harris","volume":"2018","first-page":"4107329","unstructured":null,"article-title":"Hepatitis B virus testing and care among pregnant women using commercial claims data, United States, 2011–2014","journal-title":"Infect Dis Obstet Gynecol.","doi-asserted-by":null},{"DOI":"10.1177/0033354919836958","key":"2026051211520698100_r33","year":"2019","issue":"3","author":"Koneru","volume":"134","first-page":"255","unstructured":null,"article-title":"Estimating annual births to hepatitis B surface antigen-positive women in the United States by using data on maternal country of birth","journal-title":"Public Health Rep.","doi-asserted-by":"crossref"},{"DOI":"10.1089/jwh.2011.2979","key":"2026051211520698100_r34","year":"2012","issue":"1","author":"Salihu","volume":"21","first-page":"66","unstructured":null,"article-title":"Prevalence and temporal trends of hepatitis B, hepatitis C, and HIV/AIDS co-infection during pregnancy across the decade, 1998–2007","journal-title":"J Womens Health (Larchmt).","doi-asserted-by":"crossref"},{"DOI":"10.1177/0033354916663183","key":"2026051211520698100_r35","year":"2016","issue":"5","author":"Walker","volume":"131","first-page":"685","unstructured":null,"article-title":"Characteristics of pregnant women with hepatitis B virus infection in 5 US public health jurisdictions, 2008–2012","journal-title":"Public Health Rep.","doi-asserted-by":"crossref"},{"DOI":null,"key":"2026051211520698100_r36","year":"2021","issue":null,"author":"CDC","volume":null,"first-page":null,"unstructured":null,"article-title":"Hepatitis B, Perinatal Infection 2017 Case Definition | CDC","journal-title":null,"doi-asserted-by":null},{"DOI":"10.1093/jpids/piu115","key":"2026051211520698100_r37","year":"2016","issue":"2","author":"Ko","volume":"5","first-page":"114","unstructured":null,"article-title":"Estimated annual perinatal hepatitis B virus infections in the United States, 2000–2009","journal-title":"J Pediatric Infect Dis Soc.","doi-asserted-by":"crossref"},{"DOI":null,"key":"2026051211520698100_r38","year":"2011","issue":null,"author":"CDC","volume":null,"first-page":null,"unstructured":null,"article-title":"Assessing completeness of perinatal hepatitis B virus infection reporting through comparison of immunization program and surveillance data—United States","journal-title":null,"doi-asserted-by":null},{"DOI":"10.2105/AJPH.2008.136275","key":"2026051211520698100_r39","year":"2008","issue":"5","author":"Ward","volume":"98","first-page":"779","unstructured":null,"article-title":"Time for renewed commitment to viral hepatitis prevention","journal-title":"Am J Public Health.","doi-asserted-by":"crossref"},{"DOI":"10.4269/ajtmh.1995.53.419","key":"2026051211520698100_r40","year":"1995","issue":"4","author":"Bassily","volume":"53","first-page":"419","unstructured":null,"article-title":"Comparative study of the immunogenicity and safety of two dosing schedules of hepatitis B vaccine in neonates","journal-title":"Am J Trop Med Hyg.","doi-asserted-by":"crossref"},{"DOI":"10.1097/00006454-200208000-00014","key":"2026051211520698100_r41","year":"2002","issue":"8","author":"Greenberg","volume":"21","first-page":"769","unstructured":null,"article-title":"Safety and immunogenicity of a combination diphtheria-tetanus toxoids-acellular pertussis-hepatitis B vaccine administered at two, four and six months of age compared with monovalent hepatitis B vaccine administered at birth, one month and six months of age","journal-title":"Pediatr Infect Dis J.","doi-asserted-by":"crossref"},{"DOI":"10.1016/j.vaccine.2017.11.079","key":"2026051211520698100_r42","year":"2018","issue":"4","author":"Haber","volume":"36","first-page":"559","unstructured":null,"article-title":"Safety of currently licensed hepatitis B surface antigen vaccines in the United States, Vaccine Adverse Event Reporting System (VAERS), 2005–2015","journal-title":"Vaccine.","doi-asserted-by":"crossref"},{"DOI":"10.1016/S0264-410X(01)00518-7","key":"2026051211520698100_r43","year":"2002","issue":"13–14","author":"Hieu","volume":"20","first-page":"1803","unstructured":null,"article-title":"Comparative efficacy, safety and immunogenicity of Hepavax-Gene and Engerix-B, recombinant hepatitis B vaccines, in infants born to HBsAg and HBeAg positive mothers in Vietnam: an assessment at 2 years","journal-title":"Vaccine.","doi-asserted-by":"crossref"},{"DOI":"10.1097/00006454-200111000-00009","key":"2026051211520698100_r44","year":"2001","issue":"11","author":"Lewis","volume":"20","first-page":"1049","unstructured":null,"article-title":"Safety of neonatal hepatitis B vaccine administration","journal-title":"Pediatr Infect Dis J.","doi-asserted-by":"crossref"},{"DOI":"10.1586/14760584.1.3.277","key":"2026051211520698100_r45","year":"2002","issue":"3","author":"López","volume":"1","first-page":"277","unstructured":null,"article-title":"Immunogenicity and reactogenicity of DTPw-HB/Hib vaccine administered to colombian infants after a birth dose of hepatitis B vaccine","journal-title":"Expert Rev Vaccines.","doi-asserted-by":"crossref"},{"DOI":"10.1001/archpedi.153.12.1279","key":"2026051211520698100_r46","year":"1999","issue":"12","author":"Niu","volume":"153","first-page":"1279","unstructured":null,"article-title":"Neonatal deaths after hepatitis B vaccine: the vaccine adverse event reporting system, 1991–1998","journal-title":"Arch Pediatr Adolesc Med.","doi-asserted-by":"crossref"},{"DOI":"10.1093/tropej/fmm016","key":"2026051211520698100_r47","year":"2007","issue":"5","author":"Sapru","volume":"53","first-page":"303","unstructured":null,"article-title":"Immunogenicity and reactogenicity of two recombinant hepatitis B vaccines in small infants: a randomized, double-blind comparative study","journal-title":"J Trop Pediatr.","doi-asserted-by":"crossref"},{"DOI":"10.3748/wjg.v13.i22.3084","key":"2026051211520698100_r48","year":"2007","issue":"22","author":"Velu","volume":"13","first-page":"3084","unstructured":null,"article-title":"Comparison of three different recombinant hepatitis B vaccines: GeneVac-B, Engerix B and Shanvac B in high risk infants born to HBsAg positive mothers in India","journal-title":"World J Gastroenterol.","doi-asserted-by":"crossref"},{"DOI":"10.1001/jamapediatrics.2018.2349","key":"2026051211520698100_r49","year":"2018","issue":"11","author":"Wood","volume":"172","first-page":"1045","unstructured":null,"article-title":"Immunogenicity and safety of monovalent acellular pertussis vaccine at birth: a randomized clinical trial","journal-title":"JAMA Pediatr.","doi-asserted-by":"crossref"},{"DOI":"10.1097/00006454-199706000-00009","key":"2026051211520698100_r50","year":"1997","issue":"6","author":"Yerushalmi","volume":"16","first-page":"587","unstructured":null,"article-title":"Safety and immunogenicity of a novel mammalian cell-derived recombinant hepatitis B vaccine containing Pre-S1 and Pre-S2 antigens in neonates","journal-title":"Pediatr Infect Dis J.","doi-asserted-by":"crossref"},{"DOI":"10.1097/INF.0000000000001361","key":"2026051211520698100_r51","year":"2017","issue":"1","author":"Zhu","volume":"36","first-page":"94","unstructured":null,"article-title":"Comparative efficacy, safety and immunogenicity of Hepavax-Gene TF and Engerix-B recombinant hepatitis B vaccines in neonates in China","journal-title":"Pediatr Infect Dis J.","doi-asserted-by":"crossref"},{"DOI":"10.1136/fn.81.3.F206","key":"2026051211520698100_r52","year":"1999","issue":"3","author":"Linder","volume":"81","first-page":"F206","unstructured":null,"article-title":"Unexplained fever in neonates may be associated with hepatitis B vaccine","journal-title":"Arch Dis Child Fetal Neonatal Ed.","doi-asserted-by":"crossref"},{"DOI":null,"key":"2026051211520698100_r53","year":"2025","issue":null,"author":"CDC","volume":null,"first-page":null,"unstructured":null,"article-title":null,"journal-title":null,"doi-asserted-by":null},{"DOI":"10.1097/01.inf.0000130953.08946.d0","key":"2026051211520698100_r54","year":"2004","issue":"7","author":"Eriksen","volume":"23","first-page":"656","unstructured":null,"article-title":"Lack of association between hepatitis B birth immunization and neonatal death: a population-based study from the vaccine safety datalink project","journal-title":"Pediatr Infect Dis J.","doi-asserted-by":"crossref"},{"DOI":"10.2471/BLT.24.291683","key":"2026051211520698100_r55","year":"2025","issue":"3","author":"Morgan","volume":"103","first-page":"187","unstructured":null,"article-title":"Hepatitis B vaccination of preterm infants and risk of bronchopulmonary dysplasia: a cohort study, Australia","journal-title":"Bull World Health Organ.","doi-asserted-by":"crossref"},{"DOI":"10.1097/00006454-199609000-00007","key":"2026051211520698100_r56","year":"1996","issue":"9","author":"Niu","volume":"15","first-page":"771","unstructured":null,"article-title":"Recombinant hepatitis B vaccination of neonates and infants: emerging safety data from the Vaccine Adverse Event Reporting System","journal-title":"Pediatr Infect Dis J.","doi-asserted-by":"crossref"},{"DOI":"10.1542/peds.112.5.1039","key":"2026051211520698100_r57","year":"2003","issue":"5","author":"Verstraeten","volume":"112","first-page":"1039","unstructured":null,"article-title":"Safety of thimerosal-containing vaccines: a two-phased study of computerized health maintenance organization databases","journal-title":"Pediatrics.","doi-asserted-by":"crossref"},{"DOI":null,"key":"2026051211520698100_r58","year":"2010","issue":null,"author":"Gallagher","volume":null,"first-page":"1665","unstructured":null,"article-title":"Hepatitis B vaccination of male neonates and autism diagnosis, NHIS 1997–2002","journal-title":null,"doi-asserted-by":null},{"DOI":"10.1186/2047-9158-2-25","key":"2026051211520698100_r59","year":"2013","issue":"1","author":"Geier","volume":"2","first-page":"25","unstructured":null,"article-title":"A two-phase study evaluating the relationship between Thimerosal-containing vaccine administration and the risk for an autism spectrum disorder diagnosis in the United States","journal-title":"Transl Neurodegener.","doi-asserted-by":"crossref"},{"DOI":"10.3390/toxics6040067","key":"2026051211520698100_r60","year":"2018","issue":"4","author":"Geier","volume":"6","first-page":"67","unstructured":null,"article-title":"Premature puberty and thimerosal-containing hepatitis B vaccination: a case-control study in the Vaccine Safety Datalink","journal-title":"Toxics.","doi-asserted-by":"crossref"},{"DOI":"10.1016/j.jegh.2015.06.002","key":"2026051211520698100_r61","year":"2016","issue":"2","author":"Geier","volume":"6","first-page":"105","unstructured":null,"article-title":"A longitudinal cohort study of the relationship between Thimerosal-containing hepatitis B vaccination and specific delays in development in the United States: assessment of attributable risk and lifetime care costs","journal-title":"J Epidemiol Glob Health.","doi-asserted-by":"crossref"},{"DOI":"10.1515/intox-2015-0011","key":"2026051211520698100_r62","year":"2015","issue":"2","author":"Geier","volume":"8","first-page":"68","unstructured":null,"article-title":"Thimerosal exposure and increased risk for diagnosed tic disorder in the United States: a case-control study","journal-title":"Interdiscip Toxicol.","doi-asserted-by":"crossref"},{"DOI":null,"key":"2026051211520698100_r63","year":"2004","issue":null,"author":"Immunization Safety Review IOM","volume":null,"first-page":null,"unstructured":null,"article-title":null,"journal-title":null,"doi-asserted-by":null},{"DOI":"10.1016/S0264-410X(00)00403-5","key":"2026051211520698100_r64","year":"2001","issue":"15–16","author":"Nolan","volume":"19","first-page":"2127","unstructured":null,"article-title":"A combined liquid Hib (PRP-OMPC), hepatitis B, diphtheria, tetanus and whole-cell pertussis vaccine: controlled studies of immunogenicity and reactogenicity","journal-title":"Vaccine.","doi-asserted-by":"crossref"},{"DOI":"10.1136/bmj.38719.435833.7C","key":"2026051211520698100_r65","year":"2006","issue":"7537","author":"Lee","volume":"332","first-page":"328","unstructured":null,"article-title":"Effect of hepatitis B immunisation in newborn infants of mothers positive for hepatitis B surface antigen: systematic review and meta-analysis","journal-title":"BMJ.","doi-asserted-by":"crossref"},{"DOI":"10.1093/ofid/ofx225","key":"2026051211520698100_r66","year":"2017","issue":"4","author":"Chen","volume":"4","first-page":"ofx225","unstructured":null,"article-title":"Comparative effectiveness of prophylactic strategies for perinatal transmission of hepatitis B virus: a network meta-analysis of randomized controlled trials","journal-title":"Open Forum Infect Dis.","doi-asserted-by":"crossref"},{"DOI":"10.1016/S0923-2516(97)89893-7","key":"2026051211520698100_r67","year":"1997","issue":"2","author":"Da Villa","volume":"148","first-page":"109","unstructured":null,"article-title":"Anti-HBs responses in children vaccinated with different schedules of either plasma-derived or HBV DNA recombinant vaccine","journal-title":"Res Virol.","doi-asserted-by":"crossref"},{"DOI":"10.1002/jmv.1890410107","key":"2026051211520698100_r68","year":"1993","issue":"1","author":"del Canho","volume":"41","first-page":"30","unstructured":null,"article-title":"Immunogenicity of 20 micrograms of recombinant DNA hepatitis B vaccine in healthy neonates: a comparison of three different vaccination schemes","journal-title":"J Med Virol.","doi-asserted-by":"crossref"},{"DOI":"10.1542/peds.2013-2940","key":"2026051211520698100_r69","year":"2014","issue":"6","author":"Middleman","volume":"133","first-page":"e1500","unstructured":null,"article-title":"Duration of protection after infant hepatitis B vaccination series","journal-title":"Pediatrics.","doi-asserted-by":"crossref"},{"DOI":"10.1016/j.vaccine.2012.12.012","key":"2026051211520698100_r70","year":"2013","issue":"21","author":"Schillie","volume":"31","first-page":"2506","unstructured":null,"article-title":"Seroprotection after recombinant hepatitis B vaccination among newborn infants: a review","journal-title":"Vaccine.","doi-asserted-by":"crossref"},{"DOI":"10.1097/INF.0b013e31827bd1b0","key":"2026051211520698100_r71","year":"2013","issue":"4","author":"Schönberger","volume":"32","first-page":"307","unstructured":null,"article-title":"Determinants of Long-term protection after hepatitis B vaccination in infancy: a meta-analysis","journal-title":"Pediatr Infect Dis J.","doi-asserted-by":"crossref"},{"DOI":"10.1002/hep.32474","key":"2026051211520698100_r72","year":"2022","issue":"4","author":"Bruce","volume":"76","first-page":"1180","unstructured":null,"article-title":"Protection and antibody levels 35 years after primary series with hepatitis B vaccine and response to a booster dose","journal-title":"Hepatology.","doi-asserted-by":"crossref"},{"DOI":"10.1093/infdis/jiv748","key":"2026051211520698100_r73","year":"2016","issue":"1","author":"Bruce","volume":"214","first-page":"16","unstructured":null,"article-title":"Antibody levels and protection after hepatitis B vaccine: results of a 30-year follow-up study and response to a booster dose","journal-title":"J Infect Dis.","doi-asserted-by":"crossref"},{"DOI":"10.1086/606119","key":"2026051211520698100_r74","year":"2009","issue":"9","author":"McMahon","volume":"200","first-page":"1390","unstructured":null,"article-title":"Antibody levels and protection after hepatitis B vaccine: results of a 22-year follow-up study and response to a booster dose","journal-title":"J Infect Dis.","doi-asserted-by":"crossref"},{"DOI":"10.1016/0002-9343(89)90525-1","key":"2026051211520698100_r75","year":"1989","issue":"3A","author":"André","volume":"87","first-page":"14S","unstructured":null,"article-title":"Summary of safety and efficacy data on a yeast-derived hepatitis B vaccine","journal-title":"Am J Med.","doi-asserted-by":"crossref"},{"DOI":"10.1093/infdis/160.5.766","key":"2026051211520698100_r76","year":"1989","issue":"5","author":"Jilg","volume":"160","first-page":"766","unstructured":null,"article-title":"Vaccination against hepatitis B: comparison of three different vaccination schedules","journal-title":"J Infect Dis.","doi-asserted-by":"crossref"},{"DOI":"10.4161/hv.24844","key":"2026051211520698100_r77","year":"2013","issue":"8","author":"Poovorawan","volume":"9","first-page":"1679","unstructured":null,"article-title":"Long-term anti-HBs antibody persistence following infant vaccination against hepatitis B and evaluation of anamnestic response: a 20-year follow-up study in Thailand","journal-title":"Hum Vaccin Immunother.","doi-asserted-by":"crossref"},{"DOI":"10.1111/1469-0691.12591","key":"2026051211520698100_r78","year":"2014","issue":"10","author":"Spada","volume":"20","first-page":"O680","unstructured":null,"article-title":"Hepatitis B immunity in teenagers vaccinated as infants: an Italian 17-year follow-up study","journal-title":"Clin Microbiol Infect.","doi-asserted-by":"crossref"},{"DOI":"10.1017/ice.2015.6","key":"2026051211520698100_r79","year":"2015","issue":"5","author":"Spradling","volume":"36","first-page":"529","unstructured":null,"article-title":"Response to challenge dose among young adults vaccinated for hepatitis B as infants: importance of detectable residual antibody to hepatitis B surface antigen","journal-title":"Infect Control Hosp Epidemiol.","doi-asserted-by":"crossref"},{"DOI":"10.1093/infdis/jiw142","key":"2026051211520698100_r80","year":"2016","issue":"2","author":"Simons","volume":"214","first-page":"273","unstructured":null,"article-title":"A longitudinal hepatitis B vaccine cohort demonstrates long-lasting hepatitis B virus (HBV) cellular immunity despite loss of antibody against HBV surface antigen","journal-title":"J Infect Dis.","doi-asserted-by":"crossref"},{"DOI":"10.1038/s41541-025-01188-9","key":"2026051211520698100_r81","year":"2025","issue":"1","author":"Shen","volume":"10","first-page":"126","unstructured":null,"article-title":"Level of antibody to hepatitis B surface antigen declined below 10 mIU/ml is still protective","journal-title":"NPJ Vaccines.","doi-asserted-by":"crossref"},{"DOI":"10.4161/hv.28480","key":"2026051211520698100_r82","year":"2014","issue":"6","author":"Van Der Meeren","volume":"10","first-page":"1682","unstructured":null,"article-title":"Immune memory to hepatitis B persists in children aged 7–8 years, who were vaccinated in infancy with 4 doses of Hexavalent DTPa-HBV-IPV/Hib (Infanrix Hexa) vaccine","journal-title":"Hum Vaccin Immunother.","doi-asserted-by":"crossref"},{"DOI":"10.1136/bmj.325.7364.569","key":"2026051211520698100_r83","year":"2002","issue":"7364","author":"Whittle","volume":"325","first-page":"569","unstructured":null,"article-title":"Observational study of vaccine efficacy 14 years after trial of hepatitis B vaccination in Gambian children","journal-title":"BMJ.","doi-asserted-by":"crossref"},{"DOI":"10.1371/journal.pone.0058029","key":"2026051211520698100_r84","year":"2013","issue":"3","author":"Mendy","volume":"8","first-page":"e58029","unstructured":null,"article-title":"Observational study of vaccine efficacy 24 years after the start of Hepatitis B vaccination in two Gambian villages: No need for a booster dose","journal-title":"PLOS ONE.","doi-asserted-by":"crossref"},{"DOI":null,"key":"2026051211520698100_r85","year":"2024","issue":null,"author":"CDC","volume":null,"first-page":null,"unstructured":null,"article-title":"Vaccination coverage among young children (0–35 months)","journal-title":null,"doi-asserted-by":null},{"DOI":"10.1016/j.acap.2024.04.003","key":"2026051211520698100_r86","year":"2024","issue":"6","author":"Abdus","volume":"24","first-page":"922","unstructured":null,"article-title":"Racial and Ethnic Disparities in Attendance to Well-Child Visit Recommendations during COVID-19","journal-title":"Acad Pediatr.","doi-asserted-by":"crossref"},{"DOI":"10.1542/peds.2020-1823","key":"2026051211520698100_r87","year":"2021","issue":"3","author":"Koneru","volume":"147","first-page":"e20201823","unstructured":null,"article-title":"National Perinatal Hepatitis B Prevention Program: 2009–2017","journal-title":"Pediatrics.","doi-asserted-by":"crossref"},{"DOI":"10.3201/eid1202.050038","key":"2026051211520698100_r88","year":"2006","issue":"2","author":"Coleman","volume":"12","first-page":"198","unstructured":null,"article-title":"Detecting hepatitis B surface antigen mutants - Volume 12, Number 2—February 2006 - Emerging Infectious Diseases Journal - CDC","journal-title":"Emerging Infectious Diseases.","doi-asserted-by":"crossref"},{"DOI":"10.1128/JCM.00121-06","key":"2026051211520698100_r89","year":"2006","issue":"7","author":"Ly","volume":"44","first-page":"2321","unstructured":null,"article-title":"Sensitivities of 4 new commercial hepatitis B virus surface antigen (HBsAg) assays in detection of HBsAg mutant forms","journal-title":"J Clin Microbiol.","doi-asserted-by":"crossref"},{"DOI":"10.1111/j.1423-0410.2009.01272.x","key":"2026051211520698100_r90","year":"2010","issue":"3p2","author":"Scheiblauer","volume":"98","first-page":"403","unstructured":null,"article-title":"Performance evaluation of 70 hepatitis B virus (HBV) surface antigen (HBsAg) assays from around the world by a geographically diverse panel with an array of HBV genotypes and HBsAg subtypes","journal-title":"Vox Sanguinis.","doi-asserted-by":"crossref"},{"DOI":"10.1001/jama.2019.9365","key":"2026051211520698100_r91","year":"2019","issue":"4","author":"USPSTF","volume":"322","first-page":"349","unstructured":null,"article-title":"Screening for hepatitis B virus infection in pregnant women: US Preventive Services Task Force statement","journal-title":"JAMA.","doi-asserted-by":"crossref"},{"DOI":"10.1097/00006454-199511000-00001","key":"2026051211520698100_r92","year":"1995","issue":"11","author":"Rosenthal","volume":"14","first-page":"927","unstructured":null,"article-title":"Hepatitis B virus serology in pregnant women: transmittal of results from obstetricians to pediatricians in California","journal-title":"Pediatr Infect Dis J.","doi-asserted-by":"crossref"},{"DOI":null,"key":"2026051211520698100_r93","year":"2005","issue":null,"author":"Anderson","volume":null,"first-page":null,"unstructured":null,"article-title":null,"journal-title":null,"doi-asserted-by":null},{"DOI":"10.1080/21645515.2025.2567043","key":"2026051211520698100_r94","year":"2025","issue":"1","author":"Shaw","volume":"21","first-page":"2567043","unstructured":null,"article-title":"Healthcare worker perspectives on system-level barriers to hepatitis B birth dose vaccination: an analysis in five urban U.S. hospitals","journal-title":"Human Vaccines & Immunotherapeutics.","doi-asserted-by":"crossref"},{"DOI":"10.1542/peds.2009-1831","key":"2026051211520698100_r95","year":"2010","issue":"4","author":"Willis","volume":"125","first-page":"704","unstructured":null,"article-title":"Gaps in hospital policies and practices to prevent perinatal transmission of hepatitis B virus","journal-title":"Pediatrics.","doi-asserted-by":"crossref"},{"DOI":"10.1016/S0140-6736(81)92877-4","key":"2026051211520698100_r96","year":"1981","issue":"8219","author":"Bond","volume":"1","first-page":"550","unstructured":null,"article-title":"Survival of hepatitis B virus after drying and storage for one week","journal-title":"Lancet.","doi-asserted-by":"crossref"},{"DOI":"10.1093/infdis/140.4.513","key":"2026051211520698100_r97","year":"1979","issue":"4","author":"Lauer","volume":"140","first-page":"513","unstructured":null,"article-title":"Transmission of hepatitis B virus in clinical laboratory areas","journal-title":"J Infect Dis.","doi-asserted-by":"crossref"},{"DOI":"10.1542/peds.89.2.269","key":"2026051211520698100_r98","year":"1992","issue":"2","author":"Hurie","volume":"89","first-page":"269","unstructured":null,"article-title":"Horizontal transmission of hepatitis B virus infection to United States-born children of Hmong refugees","journal-title":"Pediatrics.","doi-asserted-by":"crossref"},{"DOI":"10.1542/peds.96.6.1113","key":"2026051211520698100_r99","year":"1995","issue":"6","author":"Mahoney","volume":"96","first-page":"1113","unstructured":null,"article-title":"Continuing risk for hepatitis B virus transmission among Southeast Asian infants in Louisiana","journal-title":"Pediatrics.","doi-asserted-by":"crossref"},{"DOI":null,"key":"2026051211520698100_r100","year":"2025","issue":null,"author":"ECDC","volume":null,"first-page":null,"unstructured":null,"article-title":"Hepatitis B vaccination policies, practices and challenges to achieving hepatitis elimination in the European Union and European Economic Area","journal-title":null,"doi-asserted-by":null},{"DOI":null,"key":"2026051211520698100_r101","year":"2009","issue":null,"author":"CDC","volume":null,"first-page":null,"unstructured":null,"article-title":"Surveillance for acute viral hepatitis—United States, 2007","journal-title":null,"doi-asserted-by":null},{"DOI":null,"key":"2026051211520698100_r102","year":"2014","issue":null,"author":"CDC","volume":null,"first-page":null,"unstructured":null,"article-title":"Index of U.S. 2012 surveillance data for viral hepatitis | CDC","journal-title":null,"doi-asserted-by":null},{"DOI":null,"key":"2026051211520698100_r103","year":"2018","issue":null,"author":"CDC","volume":null,"first-page":null,"unstructured":null,"article-title":"2016 Surveillance data for viral hepatitis | CDC","journal-title":null,"doi-asserted-by":null},{"DOI":null,"key":"2026051211520698100_r104","year":"2022","issue":null,"author":"CDC","volume":null,"first-page":null,"unstructured":null,"article-title":"2020 Viral hepatitis surveillance report","journal-title":null,"doi-asserted-by":null},{"DOI":null,"key":"2026051211520698100_r105","year":null,"issue":null,"author":"CDC","volume":null,"first-page":null,"unstructured":null,"article-title":"MMWR summaries of notifiable diseases","journal-title":null,"doi-asserted-by":null},{"DOI":null,"key":"2026051211520698100_r106","year":null,"issue":null,"author":"Webinar series - Hepatitis B: education and support for health departments","volume":null,"first-page":null,"unstructured":null,"article-title":null,"journal-title":null,"doi-asserted-by":null},{"DOI":null,"key":"2026051211520698100_r107","year":"2025","issue":null,"author":"CDC","volume":null,"first-page":null,"unstructured":null,"article-title":"Viral hepatitis surveillance reports","journal-title":null,"doi-asserted-by":null},{"DOI":null,"key":"2026051211520698100_r108","year":"1984","issue":null,"author":"CDC","volume":null,"first-page":null,"unstructured":null,"article-title":"Recommendation of the Immunization Practices Advisory Committee (ACIP) Postexposure prophylaxis of Hepatitis B","journal-title":null,"doi-asserted-by":null},{"DOI":null,"key":"2026051211520698100_r109","year":"2002","issue":null,"author":"CDC","volume":null,"first-page":null,"unstructured":null,"article-title":"Notice to Readers: Recommended Childhood Immunization Schedule—United States, 2002","journal-title":null,"doi-asserted-by":null},{"DOI":"10.1001/jama.291.19.2351","key":"2026051211520698100_r110","year":"2004","issue":"19","author":"Luman","volume":"291","first-page":"2351","unstructured":null,"article-title":"Impact of thimerosal-related changes in hepatitis B vaccine birth-dose recommendations on childhood vaccination coverage","journal-title":"JAMA.","doi-asserted-by":"crossref"},{"DOI":null,"key":"2026051211520698100_r111","year":"2005","issue":null,"author":"CDC","volume":null,"first-page":null,"unstructured":null,"article-title":"A comprehensive immunization strategy to eliminate transmission of hepatitis B virus infection in the United States: Recommendations of the Advisory Committee on Immunization Practices (ACIP) part 1: immunization of infants, children, and adolescents","journal-title":null,"doi-asserted-by":null},{"DOI":"10.1542/peds.2005-2993","key":"2026051211520698100_r112","year":"2006","issue":"1","author":"Fombonne","volume":"118","first-page":"e139","unstructured":null,"article-title":"Pervasive developmental disorders in Montreal, Quebec, Canada: prevalence and links with immunizations","journal-title":"Pediatrics.","doi-asserted-by":"crossref"},{"DOI":"10.1542/peds.2004-0434","key":"2026051211520698100_r113","year":"2004","issue":"3","author":"Parker","volume":"114","first-page":"793","unstructured":null,"article-title":"Thimerosal-containing vaccines and autistic spectrum disorder: a critical review of published original data","journal-title":"Pediatrics.","doi-asserted-by":"crossref"},{"DOI":"10.1016/S0749-3797(03)00113-2","key":"2026051211520698100_r114","year":"2003","issue":"2","author":"Stehr-Green","volume":"25","first-page":"101","unstructured":null,"article-title":"Autism and thimerosal-containing vaccines: lack of consistent evidence for an association","journal-title":"Am J Prev Med.","doi-asserted-by":"crossref"},{"DOI":"10.1056/NEJMoa071434","key":"2026051211520698100_r115","year":"2007","issue":"13","author":"Thompson","volume":"357","first-page":"1281","unstructured":null,"article-title":"Early thimerosal exposure and neuropsychological outcomes at 7 to 10 years","journal-title":"N Engl J Med.","doi-asserted-by":"crossref"},{"DOI":"10.1002/pds.3482","key":"2026051211520698100_r116","year":"2013","issue":"12","author":"Iqbal","volume":"22","first-page":"1263","unstructured":null,"article-title":"Number of antigens in early childhood vaccines and neuropsychological outcomes at age 7–10 years","journal-title":"Pharmacoepidemiol Drug Saf.","doi-asserted-by":"crossref"},{"DOI":"10.1007/s00431-014-2412-5","key":"2026051211520698100_r117","year":"2015","issue":"3","author":"Mrozek-Budzyn","volume":"174","first-page":"383","unstructured":null,"article-title":"Early exposure to thimerosal-containing vaccines and children’s cognitive development. A 9-year prospective birth cohort study in Poland","journal-title":"Eur J Pediatr.","doi-asserted-by":"crossref"},{"DOI":"10.1542/peds.2010-0309","key":"2026051211520698100_r118","year":"2010","issue":"4","author":"Price","volume":"126","first-page":"656","unstructured":null,"article-title":"Prenatal and infant exposure to thimerosal from vaccines and immunoglobulins and risk of autism","journal-title":"Pediatrics.","doi-asserted-by":"crossref"},{"DOI":"10.1001/archgenpsychiatry.2007.1","key":"2026051211520698100_r119","year":"2008","issue":"1","author":"Schechter","volume":"65","first-page":"19","unstructured":null,"article-title":"Continuing increases in autism reported to California’s developmental services system: mercury in retrograde","journal-title":"Arch Gen Psychiatry.","doi-asserted-by":"crossref"},{"DOI":"10.1542/peds.2009-2489","key":"2026051211520698100_r120","year":"2010","issue":"6","author":"Smith","volume":"125","first-page":"1134","unstructured":null,"article-title":"On-time vaccine receipt in the first year does not adversely affect neuropsychological outcomes","journal-title":"Pediatrics.","doi-asserted-by":"crossref"},{"DOI":"10.1016/j.neuro.2014.06.007","key":"2026051211520698100_r121","year":"2014","issue":null,"author":"Yoshimasu","volume":"44","first-page":"121","unstructured":null,"article-title":"A meta-analysis of the evidence on the impact of prenatal and early infancy exposures to mercury on autism and attention deficit/hyperactivity disorder in the childhood","journal-title":"Neurotoxicology.","doi-asserted-by":"crossref"},{"DOI":"10.1080/23744235.2023.2258208","key":"2026051211520698100_r122","year":"2024","issue":"1","author":"Gorar","volume":"56","first-page":"1","unstructured":null,"article-title":"Impact of hepatitis B birth dose on immune response in Pakistani children: an open-label, non-inferiority randomized controlled trial, implications for achieving SDG target","journal-title":"Infect Dis (Lond).","doi-asserted-by":"crossref"},{"DOI":"10.1016/j.vaccine.2015.06.081","key":"2026051211520698100_r123","year":"2015","issue":"33","author":"Kang","volume":"33","first-page":"4093","unstructured":null,"article-title":"Efficacy of antigen dosage on the hepatitis B vaccine response in infants born to hepatitis B-uninfected and hepatitis B-infected mothers","journal-title":"Vaccine.","doi-asserted-by":"crossref"},{"DOI":"10.1371/journal.pmed.1001774","key":"2026051211520698100_r124","year":"2014","issue":"12","author":"Qu","volume":"11","first-page":"e1001774","unstructured":null,"article-title":"Efficacy of neonatal HBV vaccination on liver cancer and other liver diseases over 30-year follow-up of the Qidong hepatitis B intervention study: a cluster randomized controlled trial","journal-title":"PLoS Med.","doi-asserted-by":"crossref"},{"DOI":"10.1016/0264-410X(95)98260-H","key":"2026051211520698100_r125","year":"1995","issue":"4","author":"Lee","volume":"13","first-page":"373","unstructured":null,"article-title":"A reduced dose approach to hepatitis B vaccination for low-risk newborns and preschool children","journal-title":"Vaccine.","doi-asserted-by":"crossref"},{"DOI":"10.1093/infdis/jiab401","key":"2026051211520698100_r126","year":"2022","issue":"3","author":"Chang","volume":"225","first-page":"431","unstructured":null,"article-title":"Universal infant hepatitis B virus (HBV) vaccination for 35 years: moving toward the eradication of HBV","journal-title":"J Infect Dis.","doi-asserted-by":"crossref"},{"DOI":"10.1001/jama.1989.03420220092033","key":"2026051211520698100_r127","year":"1989","issue":"22","author":"Poovorawan","volume":"261","first-page":"3278","unstructured":null,"article-title":"Protective efficacy of a recombinant DNA hepatitis B vaccine in neonates of HBe antigen-positive mothers","journal-title":"JAMA.","doi-asserted-by":"crossref"},{"DOI":"10.1001/jama.1987.03390190090026","key":"2026051211520698100_r128","year":"1987","issue":"19","author":"Stevens","volume":"257","first-page":"2612","unstructured":null,"article-title":"Yeast-recombinant hepatitis B vaccine. Efficacy with hepatitis B immune globulin in prevention of perinatal hepatitis B virus transmission","journal-title":"JAMA.","doi-asserted-by":"crossref"}],"short-title":[],"journal-issue":{"issue":"5","published-print":{"date-parts":[[2026,5,1]]},"published-online":{"date-parts":[[2026,4,17]]}},"article-number":"e2025075783","content-domain":{"domain":[],"crossmark-restriction":false},"original-title":[],"container-title":["Pediatrics"],"published-print":{"date-parts":[[2026,5,1]]},"reference-count":128,"published-online":{"date-time":null,"timestamp":null,"date-parts":[[2026,4,17]]},"references-count":128,"short-container-title":[],"is-referenced-by-count":1},"unpaywall":{"doi":"10.1542/peds.2025-075783","is_oa":true,"title":"Hepatitis B Vaccination at Birth: Safety, Effectiveness, and Public Health Benefit","updated":"2026-02-07T14:07:32+00:00","published_date":"2026-02-05","best_oa_location":{"url":"https://publications.aap.org/pediatrics/article-pdf/doi/10.1542/peds.2025-075783/1911326/peds_2025075783.pdf","pmh_id":null,"url_for_pdf":"https://publications.aap.org/pediatrics/article-pdf/doi/10.1542/peds.2025-075783/1911326/peds_2025075783.pdf","url_for_landing_page":"https://doi.org/10.1542/peds.2025-075783"}}},"created_at":"2026-05-07T22:51:26.284Z","updated_at":"2026-05-14T15:13:26.918Z","tags":[{"paper_doi":"10.1542/peds.2025-075783","tag_type":"age_group","value":"infant","value_numeric":null},{"paper_doi":"10.1542/peds.2025-075783","tag_type":"age_group","value":"neonate","value_numeric":null},{"paper_doi":"10.1542/peds.2025-075783","tag_type":"category","value":"Pediatrics","value_numeric":null},{"paper_doi":"10.1542/peds.2025-075783","tag_type":"condition","value":"Hepatitis B","value_numeric":null},{"paper_doi":"10.1542/peds.2025-075783","tag_type":"condition","value":"Perinatal Hepatitis B Infection","value_numeric":null},{"paper_doi":"10.1542/peds.2025-075783","tag_type":"generic","value":"hepatitis B vaccine","value_numeric":null},{"paper_doi":"10.1542/peds.2025-075783","tag_type":"impact_flag","value":"practice_changing","value_numeric":null},{"paper_doi":"10.1542/peds.2025-075783","tag_type":"level_of_evidence","value":"2","value_numeric":null},{"paper_doi":"10.1542/peds.2025-075783","tag_type":"modality","value":"Vaccine","value_numeric":null},{"paper_doi":"10.1542/peds.2025-075783","tag_type":"sex","value":"mixed","value_numeric":null},{"paper_doi":"10.1542/peds.2025-075783","tag_type":"study_design","value":"Systematic Review / Narrative Review","value_numeric":null},{"paper_doi":"10.1542/peds.2025-075783","tag_type":"warning","value":"No sample size is reported — this is a review article synthesizing multiple prior studies, not a single primary study with a defined N.","value_numeric":null},{"paper_doi":"10.1542/peds.2025-075783","tag_type":"warning","value":"Study design classification is approximate — the paper combines elements of systematic review and narrative synthesis; the exact methodology (e.g., PRISMA compliance) is not described in the abstract.","value_numeric":null},{"paper_doi":"10.1542/peds.2025-075783","tag_type":"warning","value":"The ACIP vote described (December 5, 2025) represents a policy change that directly contrasts with the review's conclusions; the clinical implications are evolving and clinicians should monitor updated CDC/ACIP guidance.","value_numeric":null}],"summaries":{"what_studied":"Comprehensive review of evidence on the safety, immunogenicity, efficacy, and effectiveness of the hepatitis B birth dose vaccination versus a delayed first dose, and the role of post-vaccination serology in infants, in the context of the December 2025 ACIP vote to allow parental choice on birth dose timing.","key_result":"Strong evidence supports the safety and effectiveness of the birth dose; no improvement in safety or effectiveness was found with a delayed first dose. Post-vaccination serology was not supported for routine use. Universal infant HBV vaccination has achieved a **99% reduction** in pediatric HBV infections. No evidence supported changing the prior recommendation.","limitations":"This is a review/synthesis rather than a primary clinical trial, limiting causal inference on some endpoints. The analysis of the potential public health impact of the revised ACIP guidelines is modeled/projected rather than observed.","practice_takeaway":"The birth dose of hepatitis B vaccine remains safe and highly effective — clinicians should counsel families that delaying vaccination offers no safety or efficacy advantage and risks missing the window for perinatal protection. Routine post-vaccination immune titers in healthy infants are not supported by the evidence."}}],"initialOffset":10,"fetchConfig":{"kind":"tags","tags":[{"tag_type":"study_design","value":"Systematic Review / Narrative Review"}]},"breadcrumbItems":[{"name":"Home","href":"/"},{"name":"Research Hub","href":"/hub"},{"name":"Study Designs","href":"/hub/tag/study_design"},{"name":"Systematic Review / Narrative Review"}],"hrefConfig":{"basePath":"/hub/papers","webViewQueryParams":{"hub_ctx":"tag","hub_tag_type":"study_design","hub_tag_value":"Systematic Review / Narrative Review"}}}]]

Papers